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Proteolysis-inducing factor (PIF) is a sulphated glycoprotein produced by cachexia-inducing tumours, which initiates muscle protein
degradation through an increased expression of the ubiquitin–proteasome proteolytic pathway. The role of kinase C (PKC) in PIF-
induced proteasome expression has been studied in murine myotubes as a surrogate model of skeletal muscle. Proteasome
expression induced by PIF was attenuated by 4a-phorbol 12-myristate 13-acetate (100nM) and by the PKC inhibitors Ro31-8220
(10mM), staurosporine (300nM), calphostin C (300nM) and Go ¨ 6976 (200mM). Proteolysis-inducing factor-induced activation of
PKCa, with translocation from the cytosol to the membrane at the same concentration as that inducing proteasome expression, and
this effect was attenuated by calphostin C. Myotubes transfected with a constitutively active PKCa (pCO2) showed increased
expression of proteasome activity, and a longer time course, compared with their wild-type counterparts. In contrast, myotubes
transfected with a dominant-negative PKCa (pKS1), which showed no activation of PKCa in response to PIF, exhibited no increase in
proteasome activity at any time point. Proteolysis-inducing factor-induced proteasome expression has been suggested to involve the
transcription factor nuclear factor-kB (NF-kB), which may be activated through PKC. Proteolysis-inducing factor induced a decrease
in cytosolic I-kBa and an increase in nuclear binding of NF-kBi npCO2, but not in pKS1, and the effect in wild-type cells was
attenuated by calphostin C, confirming that it was mediated through PKC. This suggests that PKC may be involved in the
phosphorylation and degradation of I-kBa, induced by PIF, necessary for the release of NF-kB from its inactive cytosolic complex.
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Loss of skeletal muscle in cancer cachexia results in asthenia,
immobility and eventually death through impairment of respira-
tory function. Nutritional supplementation alone is unable to
reverse this wasting process (Evans et al, 1985), suggesting that the
balance between protein synthesis and degradation is impaired,
especially since visceral protein reserves are preserved and may
even increase (Fearon, 1992). Thus, while protein synthesis in
skeletal muscle of cachectic patients is impaired (Lundholm et al,
1976), there is also an increase in protein degradation (Lundholm
et al, 1982). An increased activity of the ubiquitin–proteasome
proteolytic pathway is considered to be the major factor for this
increased protein degradation (Williams et al, 1999).
Tumour production of a sulphated glycoprotein called proteo-
lysis-inducing factor (PIF) may be responsible for the progressive
loss of skeletal muscle in cancer cachexia (Todorov et al, 1996).
Proteolysis-inducing factor is only produced by cachexia-inducing
tumours, and when purified and administered to mice it induces a
specific loss of skeletal muscle, while visceral protein is maintained
or even increased, as in cancer cachexia (Lorite et al, 1998). Using
a surrogate model of skeletal muscle, PIF was shown to inhibit
protein synthesis and increase protein degradation (Smith et al,
1999). The increased protein degradation was shown to arise from
an increased expression of the ubiquitin–proteasome proteolytic
pathway (Lorite et al, 2001).
Protein degradation induced by PIF was accompanied by an
increased release of arachidonic acid from membrane phospho-
lipids and its subsequent metabolism to 15-hydroxyeicosatetrae-
noic acid (15-HETE), which was shown to be related to protein
catabolism. Both arachidonic acid and lipoxygenase metabolites
have been shown to activate protein kinase C (PKC) (Fan et al,
1990), which may play a role in PIF-induced proteasome
expression. Phosphorylation of proteasome subunits may be
important in the regulation of proteasome activity, since some
proteasome subunits have potential tyrosine (Tanaka et al, 1990)
and serine/threonine (Heinemeyer et al, 1994) phosphorylation
sites and dephosphorylation by acid phosphatase have been shown
to lower proteasome activity significantly (Mason et al, 1996). At
least one subunit (S4) has several potential PKC phosphorylation
sites (Dubiel et al, 1992). Alternatively, PKC may play a role in
activation of the transcription factor nuclear factor-kB (NF-kB),
which has been shown to be involved in the production of
interleukin-8 (IL-8), IL-6, C-reactive protein and ICAM-1 in liver
cells (Watchorn et al, 2001), and may also be involved in PIF-
induced proteasome expression (Whitehouse and Tisdale, 2003).
Protein kinase C has been suggested as being an upstream activator
of the I-kB kinase complex (IKK) (Lallena et al, 1999; Trushin et al,
1999; Vertegaal et al, 2000) leading to I-kBa phosphorylation and
ubiquitination and the subsequent processing of the 26S protea-
some followed by the translocation of NF-kB into the nucleus.
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sThe present study investigates the role of PKC in PIF-induced
proteasome expression and its relationship to activation of NF-kB
in C2C12 murine myotubes.
MATERIALS AND METHODS
Materials
Foetal calf serum (FCS), horse serum (HS) and Dulbecco’s
modified Eagle’s medium (DMEM) were purchased from Invitro-
gen (Paisley, Scotland). Mouse monoclonal antibodies to protea-
some 20S a-subunits were from Affiniti Research Products (Exeter,
UK). Rabbit polyclonal antisera to ubiquitin conjugating enzyme
(E214k) were a gift from Dr Simon Wing, McGill University
(Montreal, Canada). Rabbit polyclonal antisera to murine I-kBa,
b-tubulin and PKCa were from Calbiochem (Herts, UK) as were
PMA, Ro31-8220, calphostin C, staurosporine and Go ¨ 6976. Rabbit
polyclonal antisera to mouse actin were from Sigma-Aldridge
(Dorset, UK). Peroxidase-conjugated goat antirabbit and rabbit
antimouse secondary antibodies were from Dako Ltd (Cambridge,
UK). Hybondt nitrocellulose membranes and enhanced chemilu-
minescence (ECL) were from Amersham Life Science Products
(Bucks, UK). Electrophoretic-mobility shift (EMSA) gel shift assay
kits were from Panomics (California, USA). Escherichia coli DH5a
cells were from Invitrogen (Paisley, Scotland). Constitutively active
and mutant plasmids of PKCa were a gift from Prof. Peter Parker
(Cancer Research, UK). The insert A25E PKCa is constitutively
active due to a deletion of amino acids 22–28 in the N-terminal
region and is expressed via the pCO2 vector (Pears et al, 1990).
Protein kinase C a (T/A)3 is a dominant-negative mutant expressed
in pKS1 (Bornancin and Parker, 1996). Plasmid DNA was purified
using the WIZARD
s PureFection purification system (Promega,
Southampton, UK) according to the manufacturer’s protocol.
Primers for PCR analysis were from MWG Biotech (Ebersberg,
Germany). GeneJuicet for transfection studies was purchased
from Calbiochem (Herts, UK).
Transformation of bacteria
E. coli DH5a were transformed with both constitutively active and
mutant PKCa using heat shock, and selected with ampicillin
(100mgml
 1). Positive clones were identified using primers with
homology to bovine PKC (forward 50-CAC CTG TGA TAT GAA
CGT GC-30 reverse 50-GAA GTT GAA GTC CGT GAG C-30). The
product was about 600bp as determined on a 2% agarose gel.
Plasmid DNA was extracted from positive colonies grown over-
night in an LB medium containing ampicillin (100mgml
 1).
Purification of PIF
PIF was purified from solid MAC16 tumours excised from mice
with a weight loss between 20 and 25% as previously described
(Todorov et al, 1996; Whitehouse and Tisdale, 2003). Tumours
were homogenised in 10mM Tris-HCl, pH 8.0, containing 0.5mM
phenylmethylsulphonyl fluoride, 0.5mM EGTA and 1mM dithio-
threitol at a concentration of 5mlg
 1 tumour. The supernatant
obtained after addition of ammonium sulphate (40% wv
 1) was
subjected to affinity chromatography using anti-PIF monoclonal
antibody coupled to a solid matrix. The immunogenic fractions
were concentrated and used for further studies.
Myogenic cell culture and transfection
The C2C12 myoblast cell line was grown in DMEM supplemented
with 10% FCS plus 1% penicillin and streptomycin under an
atmosphere of 10% CO2 in air. Transfection was carried out on
cells at 50% confluency using GeneJuicet transfection reagent,
according to the manufacturer’s protocol and selected by
resistance to ampicillin (5gl
 1). Transfected myoblasts were
stimulated to differentiate by replacing the growth medium with
DMEM supplemented with 2% HS, when the cells reached
confluence. Differentiation was allowed to continue for 5–9 days
until myotubes were clearly visible, and used for the experiments
described in results.
Measurement of proteasome ‘chymotrypsin-like activity
‘Chymotrypsin-like’ enzyme activity was determined fluorimetri-
cally by the method of Orino et al (1991) as previously described
(Lorite et al, 2001). Myotubes were washed with ice-cold
phosphate-buffered saline (PBS) and sonicated in 20mM Tris-
HCl, pH 7.5, 2mM ATP, 5mM MgCl2 and 1mM dithiothreitol at
41C. The supernatant formed by centrifugation at 18000g for
10min was used to measure the ‘chymotrypsin-like’ enzyme
activity by the release of aminomethyl coumarin (AMC) from the
fluorogenic peptide succinyl-LLVY-AMC (0.1mM). Activity was
measured in the presence and absence of the specific proteasome
inhibitor lactacystin (10mM). Only lactacystin-suppressible activity
was considered to be proteasome specific.
Western blot analysis
Cytoplasmic proteins, obtained from the above assay, were also
used for Western blotting, while the pellet was dissolved in
sonicating buffer containing 0.1% Nonidet P40 and used as a
source of cell membranes. Both extracts were loaded at 2–5mg
protein and resolved on 10% sodium dodecylsulphate: polyacry-
lamide gels and transferred to Hybondt nitrocellulose membrane.
Membranes were blocked with 5% Marvel in PBS. The primary
antibodies for PKCa,E 2 14k and b-tubulin were used at a dilution of
1:100, while antibodies for I-kBa were at 1:1000 and 20S
proteasome a-subunits at 1:1500. The secondary antibodies were
used at a dilution of 1:2000. Incubation was carried out for 2h at
room temperature, and development was by ECL.
Electrophoresis mobility shift assay
DNA-binding proteins were extracted from myotubes by the
method of Andrews and Faller (1991), which utilises hypotonic
lysis followed by high salt extraction of nuclei. The EMSA-binding
assay was carried out using a Panomics EMSA ‘gel shift’ kit
according to the manufacturer’s instructions.
Statistical analysis
Differences as means between groups was determined by one-way
ANOVA followed by Tukey–Kramer multiple comparison test.
RESULTS
To evaluate the role of PKC in PIF-induced proteasome expression,
the effect of excess 4a-phorbol 12-myristate 13-acetate (PMA) on
‘chymotrypsin-like’ enzyme activity, the predominant proteolytic
activity of the proteasome (Figure 1A), and on expression of
proteasome 20Sa subunits (Figure 1B) and the ubiquitin-conjugat-
ing enzyme (E214k) (Figure 1C) was determined in C2C12 myotubes
24h after PIF addition. Proteolysis-inducing factor produced an
increase in ‘chymotrypsin-like’ enzyme activity, proteasome 20Sa
subunits and E214k with a maximal effect between 2.1 and 10nM,
and this effect was completely attenuated in myotubes pretreated
with PMA. These results suggest that PKC may be important in
PIF-induced proteasome expression.
To confirm a role for PKC in this process, the effect of Ro31-
8220, a competitive and selective PKC inhibitor (Beltman et al,
1996), staurosporine, a broad-spectrum inhibitor of protein
kinases (Couldwell et al, 1994), calphostin C, a highly specific
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sinhibitor of PKC (Jarvis et al, 1994), and Go ¨ 6976, which selectively
inhibits PKCa and b, isoenzymes (Wang et al, 1998), on the PIF-
induced increase in ‘chymotrypsin-like’ enzyme activity was
determined (Figure 2). The PIF-induced enzyme activity was
completely attenuated by 10mM Ro31-8220 (Figure 2A), 300nM
staurosporine (Figure 2B), 300nM calphostin C (Figure 2C) and
200mM Go ¨ 6976 (Figure 2D). In addition, calphostin C completely
attenuated the PIF-induced increase in proteasome 20S a-subunit
expression (Figure 3A) and E214k (Figure 3B). Proteolysis-inducing
factor induced a decrease in cytosolic PKC (Figure 4A) and an
increase in membrane-bound PKCa (Figure 4B) at the same
concentrations as those inducing proteasome expression (Figure 1)
and this effect was attenuated by both calphostin C (Figure 4A and
B) and eicosapentaenoic acid (EPA) (Figure 4D). These results
confirm a role for PKC in PIF-induced proteasome expression, and
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Figure 1 (A) Effect of PMA on PIF-induced chymotrypsin-like enzyme
activity in murine myotubes. Cells were incubated either with PIF alone
( ) or in the presence of PMA (100nM), added 2h prior to PIF (’), and
the chymotrypsin-like enzyme activity was determined after 24h, as
described in Materials and methods. The experiment was repeated three
times (n¼9). Differences from control are indicated as
aPo0.001, while
differences from cells incubated in the presence of PIF alone are shown as
bPo0.05 and
cPo0.001. (B) Western blot of the effect of PMA on
proteasome 20S a-subunits and (C)E 2 14k 24h after addition of PIF. Cells
were incubated with 0 (lanes 1 and 7), 1.0 (lanes 2 and 8), 2.1 (lanes 3 and
9), 4.2 (lanes 4 and 10), 10 (lanes 5 and 11) or 20nM PIF (lanes 6 and 12) in
the absence (lanes 1–6) or presence (lanes 7–12) of PMA (100nM). A
representative blot is shown and the experiment was repeated three times.
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Figure 2 Effect of inhibitors of PKC on PIF-induced chymotrypsin-like
enzyme activity. Myotubes were incubated with PIF alone ( ) or with Ro
31-8220 (1mM)( A); staurosporine (300nM)( B); calphostin C (300nM)
(C); or with Go 6976 (200mM)( D) added 2h prior to PIF, and
chymotrypsin-like enzyme activity was determined 24h after addition of
PIF. The experiment was repeated three times (n¼9). Differences from
control are indicated as
aPo0.05 and
bPo0.001, while differences from
cells incubated in the presence of PIF alone are shown as
cPo0.05,
dPo0.01 and
ePo0.001.
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ssuggest another mechanism by which EPA may attenuate PIF-
induced protein degradation through inhibition of PKC.
To further substantiate a role for PKC in the induction of
proteasome expression by PIF C2C12, myoblasts were transfected
with plasmids encoding constitutively active PKC-a (pCO2) and
dominant-negative PKC-a (T/A)3 (pKS1) (Bornancin and Parker,
1996; Schonwasser et al, 1998), and induced to differentiate into
myotubes. Myotubes transfected with pCO2 showed an increased
sensitivity to PIF, as determined by the ‘chymotrypsin-like’
enzyme activity (Figure 5) in comparison with wild-type myotubes,
with a significant increase within 3h of PIF addition (Figure 5A)
persisting up to 48h (Figure 5D). In addition, the elevation of
‘chymotrypsin-like’ enzyme activity in myotubes transfected with
pCO2 greatly exceeded that in wild type at all time points. In
contrast, myotubes transfected with the dominant-negative PKCa,
pKS1 showed no elevation in ‘chymotrypsin-like’ enzyme activity
in response to PIF at any time point (Figure 5). These results were
confirmed by Western blotting of cellular supernatants for 20S
proteasome a-subunit expression (Figure 6A) and E214k
(Figure 6B). Proteolysis-inducing factor induced an increase in
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Figure 3 Western blot of the effect of calphostin C on 20S proteasome
a-subunit expression (A) and E214k (B) in the presence of PIF. Cells were
incubated with 0 (lanes 1 and 6), 2.1 (lanes 2 and 7), 4.2 (lanes 3 and 8), 10
(lanes 4 and 9) or 16.8nM PIF (lanes 5 and 10) either alone (lanes 1–5) or
in the presence of calphostin C (300nM) and expression was determined
after 24h. A representative blot is shown and the densitometric analysis is
based on three replicate blots. Values in the presence of PIF are indicated
as ’ and in the presence of PIF and calphostin C as &. The densitometric
analysis of the 20S subunits represents the average of the two major bands.
Differences from control are indicated as
aPo0.05,
bPo0.01 and
cPo0.001, while differences from the presence of PIF alone are shown
as
dPo0.05,
ePo0.01 and
fPo0.001.
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Figure 4 Effect of PIF on activation of PKCa in murine myotubes in the
absence or presence of calphostin C (A, B) or EPA (C). (A) Cytoplasmic
and (B) Membrane-bound PKCa after incubation with 0 (lanes 1 and 6), 2.1
(lanes 2 and 7), 4.2 (lanes 3 and 8), 10 (lanes 4 and 9) or 16.8nM PIF (lanes
5 and 10) for 24h in the absence (lanes 1–5) or presence (lanes 6–10) of
calphostin C (300nM). The densitometric analysis was based on three
replicate blots, and values in the presence of PIF are shown as ’ and in the
presence of PIF and calphostin C as &. Differences from control are shown
as
cPo0.001, while differences from PIF alone are shown as
dPo0.05,
ePo0.01 and
fPo0.001. (C) Actin loading control for the blots shown in
(A, B). (C) Actin loading control for the blots shown in (A, B). (D) Effect
of EPA (50mM) on membrane-bound PKCa in the presence of PIF. Cells
were loaded with 0 (lanes 1 and 7), 1.0 (lanes 2 and 8), 2.1 (lanes 3 and 9),
4.2 (lanes 4 and 10), 10 (lanes 5 and 11) or 20nM PIF (lanes 6 and 12)
either in the absence (lanes 1–6) or after 2h pretreatment with EPA
(50mM), and membrane-bound PKCa was determined after 24h. (E) b-
tubulin loading control for the blot shown in (D).
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sboth proteasome a-subunit expression and E214k in pCO2 but not
pKS1, confirming a role for PKC in this process. The ability of PIF
to activate PKCa in pCO2, but not in pKS1, was confirmed by
Western blotting (Figure 7). The concentrations of PIF causing
maximum activation of PKCa were the same as those inducing 20S
proteasome a-subunit expression (Figure 6A).
We have recently shown (Whitehouse and Tisdale, 2003) that
PIF-induced proteasome expression appears to require activation
of NF-kB. One mechanism by which PKC may function in the PIF
signalling pathway is activation of IKK with subsequent phos-
phorylation and degradation of I-kB, and translocation of NF-kB
from the cytosol to the nucleus (Vertegaal et al, 2000). Evidence for
this hypothesis is provided by the following experiments.
Proteolysis-inducing factor induced a decrease in cytoplasmic
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Figure 5 Time course for induction of chymotrypsin-like enzyme activity
in wild-type myotubes ( ) and in those transfected with constitutively
active (pCO2 &) and mutant (pKS1 ’) PKCa. Myotubes were treated
with the indicated concentrations of PIF, and enzyme activity was
determined at 3h (A), 6h (B), 24h (C) and 48h (D). The experiment
was repeated three times (n¼9). Differences from control or pKS1 are
indicated as
aPo0.05,
bPo0.01 and
cPo0.005, while differences from wild-
type myotubes are indicated as
dPo0.005.
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Figure 6 Western blot of the effect of PIF on 20S proteasome a-subunit
expression (A) and E214k (B) in pKS1 (lanes 1–6) and pCO2 (lanes 7–12)
after treatment with 0 (lanes 1 and 7), 1.0 (lanes 2 and 8), 2.1 (lanes 3 and
9), 4.2 (lanes 4 and 10), 10 (lanes 5 and 11) and 20nM PIF (lanes 6 and 12)
determined after 24h. (C) b-tubulin loading control.
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Figure 7 Western blot of the effect of PIF on cytoplasmic (A) and
membrane-bound (B) PKCa in pKS1 and pCO2 after 24h. The lanes are
the same as in Figure 6.
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sI-kBa within 30min of addition to wild-type cells (Figure 8A),
accompanied by nuclear accumulation of NF-kB (Figure 8C) and
this effect was completely attenuated by calphostin C (Figure 8). In
addition, PIF induced a decrease in I-kBa (Figure 9A) and an
increase in DNA binding of NF-kB (Figure 9C) in myotubes
transfected with constitutively active PKCa (pCO2), but not in
those containing dominant-negative PKC-a (pKS1). These results
suggest that activation of PKC by PIF in muscle cells leads to I-kBa
degradation, nuclear accumulation of NF-kB and an increased
proteasome expression leading to increased intracellular protein
degradation (Whitehouse and Tisdale, 2003).
DISCUSSION
Although increased intracellular protein catabolism is a common
feature of many disease states, there is little knowledge of the
cellular signalling pathways involved, which may be useful in
therapeutic intervention. Initial studies suggested that prostaglan-
din E2 (PGE2) was involved in total protein degradation in skeletal
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Figure 8 Effect of PIF and calphostin C on cytoplasmic I-kBa (A) and
nuclear-bound NF-kB( C) determined 30min after PIF addition to murine
myotubes. (A) Myotubes were treated with 0 (lanes 1 and 6), 2.1 (lanes 2
and 7), 4.2 (lanes 3 and 8), 10 (lanes 4 and 9) or 16.8nM PIF (lanes 5 and
10) in the absence (lanes 1–5) or presence (lanes 6–10) of calphostin C
(300nM) added 2h prior to PIF. (B) Actin loading control for the blot
shown in (A). (C) Nuclear levels of NF-kB in myotubes in the absence
(lanes 2–6) or presence (lanes 7–11) of calphostin C. Lane 1 is a negative
control and lane 13 a positive control and lane 12 contains excess
unlabelled NF-kB. The other lanes were the same as in (A). The
densitometric analysis is an average of three replicate EMSAs. Differences
from control are indicated as
aPo0.05 and
cPo0.001, while differences in
the presence of calphostin C are indicated as
dPo0.01 and
ePo0.001.
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Figure 9 Effect of PIF on cytoplasmic I-kBa (A) and nuclear-bound NF-
kB( C) determined 30min after PIF addition to murine myotubes
transfected with constitutively active (pCO2 &) and mutant (pKS1 ’)
PKCa.( A) Myotubes transfected with either pCO2 (lanes 1–6) or pKS1
(lanes 7–12) were treated with 0 (lanes 1 and 7), 1.05 (lanes 2 and 8), 2.1
(lanes 3 and 9), 4.2 (lanes 4 and 10), 10 (lanes 5 and 11) or 16.8nM PIF
(lanes 6 and 12). The densitometric analysis is an average of three replicate
blots. Differences from 0nM PIF are shown as
cPo0.001. (B) Actin loading
control for the blot shown in (A). (C) EMSA of NF-kB nuclear binding in
murine myotubes transfected with pCO2 (lanes 2 and 6) and pK1 (lanes
7–11). Myotubes were treated with 0 (lanes 2 and 7), 2.1 (lanes 3 and 8),
4.2 (lanes 4 and 9), 10 (lanes 5 and 10) and 16.8nM PIF (lanes 6 and 11).
Lane 1 is a negative control containing the labelled probe without a nuclear
extract; lane 12 contains a 100-fold excess of unlabelled NF-kB probe and
lane 13 is a positive control for NF-kB (supplied by the manufacturers of
the kit). The densitometric analysis is an average of three replicate EMSAs.
Differences from control are indicated as
bPo0.01 and
cPo0.001.
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smuscle, based on the demonstration in a variety of muscle types
that tyrosine release was stimulated by arachidonic acid and PGE2
(Rodemann and Goldberg, 1982) and blocked by prostaglandin
synthesis inhibitors (Strelkov et al, 1989). However, other studies
(Hasselgren et al, 1990) found no evidence that total or
myofibrillar protein breakdown in normal or septic muscle is
regulated by PGE2. Studies with PIF showed that total protein
breakdown was related to the release of arachidonic acid and
formation of PGE2, but that PGE2 was not the eicosanoid
responsible for the effect (Smith et al, 1999). Although the
arachidonic acid was converted into a range of PGs and HETEs,
only one metabolite 15-HETE alone was capable of inducing
protein degradation. Further studies showed that 15-HETE
induced an increase in expression of the ubiquitin–proteasome
pathway, which was responsible for the initiation of protein
catabolism and that this process involved the transcription factor
NF-kB (Whitehouse et al, 2003).
The present study has investigated the possibility that PKC may
act as an intermediate in the PIF signalling pathway transmitting
the rise in 15-HETE into activation of NF-kB. The results support
the suggestion that PKC plays a central role in the induction of
proteasome expression by PIF and thus protein degradation.
Previous studies (Smith and Tisdale, 2003) have shown that PIF
induces activation of phospholipase C (PLC) as an important
signalling event in inducing proteasome expression. Activation of
PLC would result in the generation of diacylglycerol (DAG), which
would then induce translocation of PKC from the cytosol to the
membrane, resulting in the complete activation of the kinase.
Indeed, PIF has been shown to induce translocation of PKCa from
the cytosol to the membrane at the same concentrations as those
inducing proteasome expression. The importance of this step to
the induction of proteasome expression by PIF is shown by the
attenuation of this process by a range of inhibitors of PKC. In
addition, myotubes transfected with a dominant-negative mutant
of PKCa also showed no induction of proteasome expression in the
presence of PIF. Interestingly, myotubes transfected with consti-
tutively active PKCa showed an increased induction of proteasome
expression compared with their wild-type counterparts, confirm-
ing the importance of this pathway in the signalling cascade. At
present, it is not known which particular isoenzymes of PKC are
involved in this process, or indeed whether activation of PKC
occurs through production of DAG via PLC or directly through
production of 15-HETE.
Attenuation of PIF-induced activation of PKC provides another
control point where EPA may interfere with the signalling cascade
leading to increased proteasome expression. Eicosapentaenoic acid
is an effective anticachectic agent both in murine models of
cachexia (Beck et al, 1991) and in weight-losing patients with
pancreatic cancer (Barber et al, 1999), and effectively attenuates
PIF-induced proteasome expression in murine myotubes (White-
house and Tisdale, 2003). Eicosapentaenoic acid inhibits both the
release of arachidonic acid from membrane phospholipids and
formation of 15-HETE in response to PIF (Smith et al, 1999), and
stabilised the NF-kB/I-kB complex in the cytosol, preventing
nuclear accumulation of NF-kB (Whitehouse and Tisdale, 2003).
This study shows that EPA also attenuates PIF-induced activation
of PKC, which may be due to reduced generation of DAG (Sperling
et al, 1993). In addition, DAG with an n-3 polyunsaturated fatty
acid (PUFA) occupying the sn-2 position were found to be less
effective in activating PKC than DAG with an n-6 PUFA, and n-3
PUFA decreased the effectiveness of activation of PKC and
binding of phosphatidyl serine in the cell membrane (Terano
et al, 1996).
Protein kinase C a is an upstream activator of the I-kB kinase
complex (IKK) (Vertegaal et al, 2000), which phosphorylates I-kBa
at serines-32 and -36 leading to ubiquitination and subsequent
proteasome proteolysis. This suggests a mechanism by which PIF
may induce degradation of I-kBa and stimulate nuclear binding of
NF-kB (Whitehouse and Tisdale, 2003). Nuclear factor-kB
regulates the transcription of a number of genes and has been
shown (Li and Reed, 2000) to be an essential mediator of TNF-a-
induced protein catabolism in differentiated muscle cells. This
study shows that degradation of I-kBa and translocation of NF-kB
to the nucleus in response to PIF is attenuated by calphostin C and
is not seen in myotubes expressing mutant PKCa. This suggests
that PKC acts as an important mediator in activation of NF-kBi n
response to PIF. It is not known whether NF-kB acts alone or in
concert with other transcriptional activators in PIF-induced
proteasome expression and future studies will be aimed at
identifying the role of NF-kB in this process.
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